ArticleEmerging microbes & infections2017
Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
Article in Emerging microbes & infections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- High pathogenicity of human adenovirus type 55 in adult males: a meta-analysis and phylogenetic study of HAdV-55 epidemics worldwide over the past six decades.Emerging microbes & infections · 2026Pooled it
- A replication-incompetent adenovirus type 55 vaccine induces broad and durable protective immunity against pathogenic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- The seroprevalence of adenoviruses since 2000Emerging microbes & infections · 2025Review
- High-level adenovirus-neutralizing antibodies plasma beneficial for adenovirus type 7 (Adv7) induced pediatric severe ARDS.Journal of virus eradication · 2025Article
- Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews.Emerging microbes & infections · 2024Article
- Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021.Intervirology · 2024Review
- Generation of Human Embryonic Stem Cell-Derived Lung Organoids for Modeling Infection and Replication Differences between Human Adenovirus Types 3 and 55 and Evaluating Potential Antiviral Drugs.Journal of virology · 2023Article
- Generation and Characterization of a Replication-Competent Human Adenovirus Type 55 Encoding EGFP.Viruses · 2023Article
- A seroepidemiological survey of adenovirus type 7 circulation among healthy adults in China and in Sierra Leone, West Africa.Frontiers in public health · 2023Article
- Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.Virologica Sinica · 2022Article
- A Sensitive and High-Throughput Flow Cytometry-Based Assay for Measuring Antibody Neutralization of Human Adenovirus Type 3.Virologica Sinica · 2021Article
- Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China.Virologica Sinica · 2021Article
- Ongoing outbreak of human adenovirus-associated acute respiratory illness in the Republic of Korea military, 2013 to 2018.The Korean journal of internal medicine · 2021Article
- Human Desmoglein-2 and Human CD46 Mediate Human Adenovirus Type 55 Infection, but Human Desmoglein-2 Plays the Major Roles.Journal of virology · 2020Article
- Human Adenovirus Type 55 Distribution, Regional Persistence, and Genetic Variability.Emerging infectious diseases · 2020Article
- Epidemiology and Genetic Variabilities of Human Adenovirus Type 55 Reveal Relative Genome Stability Across Time and Geographic Space in China.Frontiers in microbiology · 2020Article
- Seroprevalence of neutralizing antibodies against human adenovirus type 55 in the South Korean military, 2018-2019.PloS one · 2020Article
- Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob.Emerging microbes & infections · 2018Article
- Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa.Emerging microbes & infections · 2018Article
- An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.Emerging microbes & infections · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Re-emerging human adenovirus types 14 (Ad14) and 55 (Ad55) have caused severe respiratory diseases and even deaths during recent outbreaks. However, the seroprevalence of neutralizing antibodies (nAbs) in healthy adults, which may reflect previous circulation and help to predict potential outbreaks, remains unclear. In this study, we established micro-neutralizing (MN) assays on the basis of recombinant Ad14 and Ad55 reporter viruses, and we investigated serum nAbs in healthy blood donors from Southern China. We found that the overall seropositive rates were 24.8% and 22.4% for Ad14 and Ad55 nAbs, respectively. The seropositive rates were low in individuals younger than 20, and they gradually increased with age. Ad55-seropositive individuals tended to have high nAb titers (>1000), while low (72-200) and moderate (201-1000) nAb levels were frequently observed in Ad14-seropositive ones. Surprisingly, the seropositive rates and nAb levels were associated with the blood type but not the gender of the blood donors, with type AB individuals displaying higher seropositive rates and nAb levels. Interestingly, a significant positive correlation was observed between Ad14 and Ad55 seroprevalence, and higher titers of nAbs were detected in double-positive individuals compared to single-positive ones. These results clarified the human humoral immune responses against Ad14 and Ad55 and revealed a low level of herd immunity in some subpopulations, which emphasized the importance of monitoring these two highly virulent adenoviruses and reinforced the development of prophylactic vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.